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Abstract
Background: Organ-specific autoimmune diseases affect particular targets in the body, whereas systemic
diseases engage multiple organs. Both types of autoimmune diseases may coexist in the same patient,
either sequentially or concurrently, sustained by the presence of autoantibodies directed against the
corresponding autoantigens. Multiple factors, including those of immunological, genetic, endocrine and
environmental origin, contribute to the above condition. Due to association of certain autoimmune
disorders with HLA alleles, it has been intriguing to examine the immunogenetic basis for autoantigen
presentation leading to the production of two or more autoantibodies, each distinctive of an organ-specific
or systemic disease. This communication offers the explanation for shared autoimmunity as illustrated by
organ-specific blistering diseases and the connective tissue disorders of systemic nature.
Presentation of the hypothesis: Several hypothetical mechanisms implicating HLA determinants,
autoantigenic peptides, T cells, and B cells have been proposed to elucidate the process by which two
autoimmune diseases are induced in the same individual. One of these scenarios, based on the assumption
that the patient carries two disease-susceptible HLA genes, arises when a single T cell epitope of each
autoantigen recognizes its HLA protein, leading to the generation of two types of autoreactive B cells,
which produce autoantibodies. Another mechanism functioning whilst an epitope derived from either
autoantigen binds each of the HLA determinants, resulting in the induction of both diseases by cross-
presentation. Finally, two discrete epitopes originating from the same autoantigen may interact with each
of the HLA specificities, eliciting the production of both types of autoantibodies.
Testing the hypothesis: Despite the lack of immediate or unequivocal experimental evidence
supporting the present hypothesis, several approaches may secure a better understanding of shared
autoimmunity. Among these are animal models expressing the transgenes of human disease-associated
HLA determinants and T or B cell receptors, as well as in vitro binding studies employing purified HLA
proteins, synthetic peptides, and cellular assays with antigen-presenting cells and patient's lymphocytes.
Indisputably, a bioinformatics-based search for peptide motifs and the modeling of the conformation of
bound autoantigenic peptides associated with their respective HLA alleles will reveal some of these
important processes.
Implications of the hypothesis: The elucidation of HLA-restricted immune recognition mechanisms
prompting the production of two or more disease-specific autoantibodies holds significant clinical
ramifications and implications for the development of more effective treatment protocols.
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Background
Autoimmune mucocutaneous blistering diseases (AMBD)
such as pemphigus vulgaris (PV), pemphigus foliaceus
(PF), bullous pemphigoid (BP), and mucous membrane
pemphigoid (MMP), are a group of rare organ-specific dis-
eases that affect skin and multiple mucous membranes [1-
5]. PV is a potentially fatal disease characterized by the
loss of intercellular adhesion of keratinocytes, resulting in
acantholysis [6-8]. In the serum of PV patients, high titers
of circulating autoantibodies targeting the epidermal
adhesion molecule desmoglein 3 (Dsg3), one of the kerat-
inocyte transmembrane proteins localized in the desmo-
some, which is essential for maintaining the integrity of
the epidermis, are believed to cause clinical disease by
direct binding to and disruption of desmoglein proteins
[1,9]. The association of HLA antigens with the suscepti-
bility to PV has been demonstrated in numerous studies
[10-14]. It appears that PV is tightly linked to a rare hap-
lotype HLA-DR4 (DRB1*0402) DQwB1*0302 in
Ashkenazi Jews. In non-Jewish patients the haplotype is
HLA-DRB1*404, DQB1*0503 [15].
Another blistering disease, MMP, which affects mucous
membranes of the body, is characterized by the presence
of autoantibodies to human β4 integrin [16,17], while BP
which predominantly affects the skin, is associated with
bullous pemphigoid antigen 1 (BPAg1) and (BPAg2) [18].
Both BP and MMP have been shown to have a strong link-
age to HLA-DQB1*0301 [18,19]. It has been demon-
strated that the same patient may have antibodies against
more than one autoantigen within the skin and mucous
membrane resulting in more than one autoimmune
mucocutaneous disease. For example, patients with PF
may develop BP [20,21]; patients with MMP may have PV
[22], and some patients are affected with both PV and
ocular cicatricial pemphigoid [23].
In contrast to organ-specific diseases, connective tissue
disorders, or systemic diseases, including systemic lupus
erythematosus (SLE), rheumatoid arthritis (RA), and sys-
temic sclerosis (SSc), involve multiple tissues and organs
[24-26]. Mixed connective tissue disease (MCTD) is a sys-
temic autoimmune syndrome characterized by the pres-
ence of high titers of serum antibodies against small
nuclear ribonuclearproteins (U-snRNPs) [27,28], in par-
ticular against U1 small nuclear RNP polypeptide (U1
snRNP). It has been suggested that MCTD represents a dis-
tinct clinical entity, based on clinical manifestations that
separate MCTD from other connective tissue diseases
[29]. Various associations of HLA antigens with MCTD
have been reported, including HLA-B7 and HLA-Dw1
[30]. In another study, DR4 was found to be significantly
increased in MCTD [31], whereas others reported an asso-
ciation between HLA-DQw3 and anti-RNP antibodies in
patients with MCTD [32]. Interestingly, MCTD patients
with increased IgG autoantibodies against U1–70 kD
polypeptide have an increased prevalence of DR4 antigen
compared with controls [33]. Furthermore, molecular
biology studies have shown that most MCTD patients car-
rying DR4 or DR2 alleles share a region of homology con-
sisting of seven amino acids in the DRB1 gene [34]. This
"shared epitope" of DR molecules, in different alleles and
in different patients with MCTD, may be important for the
modulation of the autoimmune response to the U1–70
kD antigen [35]. HLA associations with organ-specific and
systemic autoimmune disorders and their autoantigens
are listed in Table 1.
It has been well documented that autoimmune diseases
may coexist in the same patient, either sequentially or
concurrently [21,36-46]. PV, dermatitis herpetiformis, BP,
and SLE have all been reported in association with other
autoimmune diseases as well as with each other. In partic-
ular, observations of dual autoimmunity in some patients
who concurrently develop organ-specific and systemic
disease have been reported [38,40,41,44,46]. Multiple
factors, including those of immunological, genetic, endo-
crine and environmental origin, contribute to the above
condition. The immunogenetic mechanisms of this phe-
nomenon present an intriguing unresolved problem of
autoimmune predisposition, calling for development of
prospective approaches of prediction and ultimately pre-
vention of the disease. As a matter of fact, the involvement
of T cells in immunopathogenesis of MCTD, PV and MMP
has been well established. In MCTD, the role of anti-RNP-
reactive T cells in autoantibody production has been dem-
Table 1: HLA associations with Mixed Connective Tissue Disease and Autoimmune Blistering Diseases
Disease HLA allele Autoantigen Reference
Mixed Connective Tissue Disease HLA-B7, HLA-Dw1
HLA-DQw3
U1 sn-RNP polypeptide
U1 sn-RNP polypeptide
30
32
Mucous Membrane Pemphigoid HLA-DQB1*0301 β4 integrin 19, 64
Bullous Pemphigoid HLA-DQB1*0301 BPAg1 (BP180)
BPAg2 (BP230)
18, 64
Pemphigus Vulgaris HLA-DR4 (DRB1*0402), 
DQwB1*0302
HLA-DRB1*404, DQB1*0503
Dsg3
Dsg3
65
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onstrated [47,48]. In PV, it has been shown that B cells
function as antigen-presenting cells stimulating Dsg3-spe-
cific CD4+ T helper (Th) cells to secrete cytokines such as
interleukin (IL)-4, IL-6 and IL-10 which are required for
proliferation of memory B cells and differentiation into
antibody-producing plasma cells [49-51]. Thus, the inter-
play between B and T cells seems to be critical, which is
further supported by the finding that depletion of CD4+ T
cells prevents antibody production (reviewed in ref. [52]).
Moreover, a clinical study showed that the mean fre-
quency of Th2 CD4+ T cells was significantly elevated in
PV patients with active disease, while no responses were
detected for patients with disease in remission or controls
[53]. Characterization of autoreactive T-cells has led to
identification of immunodominant T-cell epitopes and
the repertoire of Dsg3- or Dsg1-specific T-cells at the
clonal level [54,55]. Lastly, the potential role for antigen-
specific autoreactive T cells in the pathogenesis of MMP
has also been addressed [56,57].
Collectively, these observations suggest that T cell
epitopes of the respective autoantigens, i.e. Dsg-3 for PV,
β4 integrin for MMP, and U1 snRNP for MCTD, may bind
to their HLA molecules and trigger the activation of auto-
reactive T cells, which in turn would induce production of
pathogenic autoantibodies. This mechanism would most
probably be applicable to the case of a single disease,
however, when two or more autoimmune diseases occur
in the same patient, the molecular and cellular events are
likely to be more complex. Based on the accumulated evi-
dence of shared autoimmunity, it has been intriguing to
investigate the relationship between the genetic and
immunological mechanisms for the simultaneous pro-
duction of two or more autoantibodies. A hypothesis,
which in part may explain some of the increased suscepti-
bility to both autoimmune blistering and systemic con-
nective tissue diseases, is presented below.
Presentation of the hypothesis
The schematic representation of the possible immun-
opathogenic mechanisms leading to breakage of tolerance
and induction of the two autoimmune diseases in the
same individual is shown in Fig. 1. Theoretically, there
can be at least three possible scenarios. The first scenario
(left panel, Single HLA Recognition) may apply to the sit-
uation when T cell epitopes of the two different autoanti-
gens associate with each of the susceptible HLA
molecules, resulting in dual autoimmunity. It will occur
when a single epitope of an autoantigen recognizes the
disease-linked HLA determinant. For example, in the
patient with MCTD and PV, carrying two DR4 alleles, one
DR4 allele may bind to the relevant epitope within U1-
snRNP antigen and produce anti-RNP antibodies. The sec-
ond DR4 allele, such as DRB1*0402 may bind the rele-
vant epitope of Dsg3 and result in the production of
autoantibodies to Dsg3. In another instance, the DQB
allele such as DQB1*0301 could present the BP or MMP
antigens and thus induce antibodies to BPAg2 or human
β4 integrin subunit. Based on whether the antigen pre-
sented is BPAg2 or β4 integrin subunit, the patient may
have BP or MMP, respectively.
In support to this mechanism, it is noteworthy that the
affinity of the binding between the autoantigenic peptide
epitope, the susceptible HLA and the TCR plays an impor-
tant role in T cell activation. Due to certain degree of pro-
miscuity and specificity in peptide recognition by the HLA
receptors, not a single binding affinity, but rather a range
of affinities would account for the productive interaction
between the peptide epitope, HLA and the TCR, leading to
T cell-mediated B cell activation and antibody secretion.
Of the three autoantigens mentioned in the present study,
i.e. snRNP, β4 integrin and Dsg-3, the latter has been char-
acterized most extensively in terms of epitope mapping
and HLA binding capacity. Modeling of the bound con-
formation of PV-associated peptides revealed the role of
DRB1*0402 in the selection of specific self-epitopes [58].
Several studies suggest that autoantigenic peptides do not
necessarily bind to disease-associated HLA molecules with
high affinity, but rather within the intermediate range,
thus allowing for the rescue of autoreactive T cells. In con-
trast, protective HLA proteins are more efficient binders of
self-antigens, which results in elimination of autoreactive
T cells [58].
The second scenario (Figure 1, central panel, Dual HLA
Recognition) applies to the situation when a single
epitope of an autoantigen binds to both HLA specificities,
leading to the induction of both diseases by cross-presen-
tation and reactivity. Thus, it can not be excluded that
there is cross-reactivity in the binding of immunopatho-
genic epitopes to either of the susceptible genes in the
same individual, leading to T cell responses which trigger
autoantibody production. For example, if an epitope
within Dsg3, β4 integrin, BPAg2, or U1-snRNP is available
for antigen presentation, it is possible that such a peptide
with the complete homology is present in all four mole-
cules or only in one molecule. However this specific
epitope might have the capacity to bind to different HLA
determinants. If it binds to DR2 or DR4, it stimulates T
cells that induce activation of B cells producing anti-RNP
antibodies. If it binds to DRB1*0402 or DQB1*0503, it
results in stimulating T cells inducing production of anti-
Dsg3 antibodies. If it binds to DQB1*0301, it stimulates
T cells leading to generation of autoantibodies to BPAg2
or β4 integrin.
It should be noted that peptide binding to HLA is facili-
tated by the interactions between the amino acid residues
lining the groove of HLA molecules and the side chains ofJournal of Autoimmune Diseases 2008, 5:1 http://www.jautoimdis.com/content/5/1/1
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the bound peptide. The binding pockets of HLA class II,
defined by the polymorphic β chain and the more con-
servative α chain of the αβ heterodimer, share homology
between some alleles but may also differ from other alle-
les as defined by size, charge and hydrophobicity [59].
Thus, peptides derived from different autoantigens may
not share sequence homology, but still be able to bind dif-
ferent HLA due to the presence of certain amino acids
which would fit to the binding pockets of the HLA mole-
cules. Given that the sequences of Dsg-3, snRNP and β4
integrin are all different, it is unlikely that the immunodo-
minant epitopes of each of these antigens would contain
similar amino acid sequence. In spite of this fact, the two
peptides may share common binding motifs, dictated by
structural requirements of the HLA pockets accommodat-
ing the peptides. Due to the degenerate nature of the HLA
binding and TCR recognition, the observation which has
been widely accepted for the past decade [60], common
binding motifs would be sufficient to allow peptide bind-
ing to the same HLA molecule. However, in this case, it is
possible that the recognition of the HLA/peptide complex
by T cells will differ depending on the orientation of the
TCR interacting with the amino acids facing away from
the binding groove, and thus will result in differential acti-
vation by T cells.
The third scenario is presented on the right panel of Figure
1 (Dual HLA Recognition). It is conceivable that two dis-
tinct epitopes of the same autoantigen are able to bind
two HLA specificities associated with the two diseases,
implying that both T cell epitopes originating from one
autoantigen will activate immunopatogenic mechanisms
by binding to two HLA molecules specific for two dis-
eases. For instance, the patient has a single autoantigen
such as Dsg3 or U1-snRNP. One epitope within this mol-
ecule may bind to the DR4 or DR2 allele associated with
MCTD, resulting in anti-RNP antibody production. This
would presume that certain sequences within Dsg3 are
similar to sequences within U1sn-RNP. A second epitope
within the same molecule may bind to the other DR/DQ
Immunogenetic mechanisms of dual autoimmunity Figure 1
Immunogenetic mechanisms of dual autoimmunity. Coexistence of two autoimmune disorders in the same patient 
may occur due to multiple mechanisms. Schematic representation of the potential pathways leading to the induction of PV and 
MCTD is shown on the three panels. Based on the assumption that production of autoantibodies is triggered by T cells inter-
acting with the autoantigenic epitopes bound to the susceptible HLA alleles, the following scenarios are described: 1 (left panel, 
Single HLA recognition). In this case, each T cell epitope specific for a single disease may associate with its susceptible HLA 
protein, leading to T cell activation and subsequent stimulation of B cells to produce autoantibodies, which would result in dual 
autoimmunity. 2 (central panel, Dual HLA Recognition). Here, each of the disease-specific autoantigens may bind to either HLA 
protein, leading to the induction of both diseases by cross-presentation. 3 (right panel, Dual HLA Recognition). According to 
this scenario, two distinct epitopes of the same autoantigen may be able to bind two disease-associated HLA molecules. Similar 
pathways would apply to the situation when MCTD and MMP are presented in the same patient.Journal of Autoimmune Diseases 2008, 5:1 http://www.jautoimdis.com/content/5/1/1
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allele which has the genotype associated with PV, i.e.
DRB1*0402 or DQB1*0503, and produce antibodies to
Dsg3. Hence, there is no cross reactivity between the two
epitopes within the same molecule. However, the autoan-
tibodies produced are different because the alleles to
which they bind are different, yet specific for each disease.
In this respect, it is of notion that epitopes derived from a
single antigen may be generated in the course of antigen
processing and presentation. Since these peptides differ in
amino acid sequence and most probably bind HLA with
differential affinities, it is possible that T cells interacting
with the APC may also have different specificities. Thus, it
is not excluded that some of these peptides, derived from
one antigen, will have the potential to trigger T cells spe-
cific for the second antigen by virtue of cross-reactivity.
Consequently, distinct B cell clones will be activated and
induced to secrete each a different autoantibody. In this
case, B cells may also serve as the APC.
Testing the hypothesis
Molecular and cellular mechanisms governing concur-
rent or sequential presence of autoimmune blistering and
systemic diseases in patients remain to be elucidated.
Although there is no immediate or unequivocal experi-
mental evidence to support the present hypothesis, sev-
eral approaches might hold a promise for the better
understanding of the shared autoimmunity. Investiga-
tion of these mechanisms has been significantly delayed
due to the lack of animal models in which both the sys-
temic and organ-specific autoimmune diseases can be
induced. To this end, only a small number of experimen-
tal models of susceptibility to a single disease have been
developed with limited success [61-63]. Development of
such animal models allowing investigation of the effects
of the triggering factors on shared autoimmunity would
require genetic manipulations enabling to introduce the
elements of susceptibility, i.e. human HLA and/or
autoantigen-specific TCR/BCR. Thus, a transgenic mouse
model expressing two disease-associated HLA and two
TCR/BCR specific for each of the autoantigenic peptides
would be most suitable for this purpose. In these mice,
the experimental approach would contain the adminis-
tration of disease-inducing peptides, separately or con-
comitantly, and monitoring the animals for
manifestations of each disease. In parallel, ex-vivo func-
tional analysis including antigen-specific proliferation,
cytokine secretion and antibody phenotyping, has to be
performed. The in vitro binding studies employing puri-
fied HLA proteins and synthetic peptides, and the cellular
assays with antigen-presenting cells and patient's lym-
phocytes would also be instrumental. Undoubtedly, bio-
informatics-based search for peptide motifs and the
modeling of the bound conformation of the autoanti-
genic peptides associated with the respective HLA alleles
will shed light on some of these important processes.
Implications of the hypothesis
The hypothesis presented above could partially explain
the simultaneous production of two or more pathogenic
antibodies in patients having a blistering and a systemic
autoimmune disease, as reported over the past decades
[21,36-46]. Further studies of these patients, and espe-
cially of T and B lymphocytes administered into HLA-
transgenic mice, will provide valuable information on cel-
lular and molecular mechanisms critical for immunoreg-
ulation and production of pathogenic autoantibodies.
Such studies have significant clinical ramifications and
implications for the development of novel immune ther-
apies targeting both autoimmune diseases.
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